Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inviragen and Advanced BioScience Laboratories (ABL), a biomedical contract research and manufacturing organization, have signed a contract manufacturing agreement.
Subscribe to our email newsletter
Under the agreement, ABL will be responsible for the production and characterization of a master virus seed stock, a reservoir of virus produced under strict cGMP conditions.
The master virus seed stock will be used to support Inviragen’s development of a vaccine against plague.
ABL will also develop purified vaccine material to be used in future toxicology studies.
ABL CEO Thomas VanCott said that their expertise in cGMP manufacturing of viral products will provide Inviragen with the support they need in their development of a plague vaccine candidate.